Results from a phase Ib trial combining vadastuximab talirine to 7 + 3 induction therapy suggests deeper and more rapid remissions, without added nonhematologic toxicity, for patients with newly diagnosed AML.
Phase II trial suggests durable, MRD-negative CR in 82% of patients after infusion of CTL019 CAR T-cells.
In this subanalysis of the phase III TOWER study, blinatumomab demonstrated superior health-related QoL vs standard-of-care chemotherapy in patients with R/R Ph- B-Precursor ALL.
The combination of inotuzumab ozogamicin with lower-intensity mini-HCVD chemotherapy in older patients with ALL resulted in a high ORR and low early mortality.
In this phase I trial, vadastuximab talirine plus HMA was active in higher-risk patient subsets, including patients with advanced secondary AML and those older than 75 years of age.
ABL001 showed early indications of clinical activity in chronic-phase CML patients both with and without TKI resistance mutations.
In this phase II open-label study, the combination of ponatinib with hyper-CVAD resulted in high complete cytogenetic and molecular response rates in patients with Ph+ ALL.
Factors associated with MRFS after TKI cessation included longer durations of imatinib therapy, MR4, and pretreatment IFN.
In this phase III trial, idarubicin plus high-dose cytarabine with or without vorinostat did not show superiority to 7 + 3 regimen in untreated AML patients 60 years of age or younger.
In this text module and accompanying downloadable slideset, experts review the most clinically relevant study results presented at Hematology 2016 in acute myeloid leukemia, acute lymphoblastic leukemia, and chronic myeloid leukemia.
In this downloadable slideset, Elias Jabbour, MD, and Farhad Ravandi, MD, review key studies and data presented at the 2016 American Society of Hematology annual meeting relevant to the management of patients with acute or chronic leukemias.